Ultragenyx Pharma (NASDAQ: RARE) reported Q1 EPS of $0.62, versus ($0.19) reported last year. Revenue for the quarter came in at $10.68 million versus the consensus estimate of $52.86 million.

“With the recent approvals and launches of Crysvita in the United States and Europe, we have transformed into a commercial stage company with two medicines now available for patients,” said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx. “We continue to advance our clinical and preclinical programs and expect significant progress across our two clinical-stage gene therapy programs as well as our small molecule and biologics programs this year.”

For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.